Analog Devices and TWAICE Work Together to Advance Battery Lifecycle Optimization
2.9.2021 16:00:00 EEST | Business Wire | Press release
Battery analytics software expert TWAICE today announced a collaboration with Analog Devices, Inc., a global semiconductor and system solutions company, to tackle the challenges of battery lifecycle optimization. The combination of Analog Devices’ sensor technology and wireless connectivity with TWAICE’s battery analytics software will benefit customers in the mobility and energy sectors. The alliance will be instrumental in significantly reducing warranty risks and recalls, optimizing battery life, and enhancing battery value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005016/en/
TWAICE Battery Testing Laboratory in Munich, Germany. Photo: TWAICE
Analog Devices is a global leader in battery management systems, and high-performance analog, mixed-signal, and digital signal processing solutions. The collaboration with the software company TWAICE, whose platform provides end-to-end battery analytics solutions, will enable the optimization of the entire battery lifecycle.
Mobility is at an inflection point, with electrified powertrains replacing combustion engines. Battery reliability and economics are critical in the widespread deployment of renewable energies and electric vehicles. Battery performance and lifespan play a key role in the sustainability of solutions they are deployed in, yet the assessment thereof is often challenging. “Precision data combined with advanced predictive battery analytics will shed light into the darkness, which is crucial in unlocking as yet undiscovered potential along the entire value chain," said Dr. Stephan Rohr, Co-CEO of TWAICE.
“The battery is the energy source for every electric vehicle, and it is also a valuable asset,” said Patrick Morgan, Vice President of Automotive at Analog Devices. “Together with TWAICE, we are delivering innovative holistic solutions across battery lifetimes that create significant value for our customers and support a circular economy.”
The goal of the collaboration is to provide a holistic lifecycle solution for automakers with integrated hardware and software. Accurate battery measurements provided through a wireless battery management system form the basis. Analog Devices’ sensor technology provides data, and a quality thereof previously unavailable. TWAICE can generate crucial insights into the battery performance desired by companies around the globe. The resulting forecasts enable qualified statements at any point in the battery lifecycle regarding its value and usability.
About Analog Devices Inc.
Analog Devices (ADI), headquartered in Norwood, Massachusetts, is a global leader in the design, manufacture and marketing of a broad portfolio of high-performance analog, mixed-signal, DSP circuits and microchips used in virtually all types of electronic devices. With over 55 years of market experience, 16,000 employees worldwide today, over 4,700 patents and 125,000 customers in instrumentation, automation, communications, healthcare, automotive and numerous other industries, Analog Devices is dedicated to solving technical challenges associated with signal processing in electronic devices. More at www.analog.com.
About TWAICE
TWAICE provides predictive analytics software that optimizes both the development and operation of lithium-ion batteries. As the leading provider of battery analytics software to global electric vehicle and energy companies, TWAICE increases the longevity, efficiency and sustainability of products that drive tomorrow's economy. More at www.twaice.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005016/en/
Contact information
Anna Lossmann
press@twaice.com
PR13
twaice@pr13.de
+49 40 21993366
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom